How to Learn Pharmacovigilance Step by Step: A Complete Beginner's Guide 2026 If you have just started exploring pharmacovigilance, you probably know the feeling — there is a lot of information out there, but it is hard to know where to begin. Do you start with adverse drug reactions? Or regulatory guidelines? Or case processing? The truth is, pharmacovigilance has a natural learning order. Jumping into signal detection before understanding what an ICSR is will only make things more confusing. This guide is designed to give you a clear, logical roadmap — step by step — so that every new concept builds on what you already know. Whether you are a pharmacy graduate, a life sciences student, or someone switching careers into drug safety, this complete guide will walk you through everything you need to learn. Quick Navigation What is Pharmacovigilance Key Terminologies Adverse Drug Reactions ICSR Processing Causality Assessment Narrative Writing Medical Coding Regulatory Reporting Agg...
Get link
Facebook
X
Pinterest
Email
Other Apps
Introduction to Pharmacovigilance (PV): Definition, History and Key Concepts for Beginners
Get link
Facebook
X
Pinterest
Email
Other Apps
Introduction to Pharmacovigilance (PV): Definition, History and Key Concepts for Beginners
Introduction
Pharmacovigilance (PV) is an essential discipline in healthcare that focuses on ensuring the safety of medicines. Since no drug is completely free from risk, continuous monitoring is required to detect and prevent adverse effects and to protect patients and public health.
This blog explains the basic concepts of Pharmacovigilance, including its definition, objectives, scope, types, and historical background. It is especially useful for students, freshers, and beginners in Pharmacovigilance.
To make it easier, watch this short video explaining the basics of pharmacovigilance in a clear and simple way.
What is Pharmacovigilance?
Pharmacovigilance is a medical profession and scientific discipline that involves activities aimed at promoting and safeguarding patient safety and public health.
According to the World Health Organization (WHO),
Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and preventionof adverse events or any other drug-related problems.
In routine pharmacovigilance practice, safety data are primarily managed through Individual Case Safety Reports (ICSRs). To understandhow case handling works step-by-step, read our detailed guide on ICSR processing in pharmacovigilance.
Objectives and Scope of Pharmacovigilance:
Pharmacovigilance involves:
Studying the causal relationship between an administered drug and an observed adverse event
Detecting, assessing, and preventing adverse drug reactions (ADRs). A clear understanding of the types of adverse drug reactions is essential for accurate drug safety monitoring.
Promoting safe and rational use of medicines
Safeguarding public health related to medication use
Creating awareness among:
Patients, General public, Healthcare professionals (HCPs)
During case assessment, professionals must also clearly understand the difference between seriousness and severity in pharmacovigilance, as both impact regulatory reporting decisions.
Meaning and Origin of the Term Pharmacovigilance
The word Pharmacovigilance is derived from two languages:
This indicates that medicines must always be monitored, as they can cause adverse events at any time and are not completely safe under all circumstances.
When Does Pharmacovigilance Start?
Pharmacovigilance begins:
From the day an Investigational New Drug (IND) is first tested in human clinical trials
Continues throughout:
Clinical development
Post-marketing surveillance
Until the drug is withdrawn from the market
Important Notes
Pharmacovigilance is not applicable to pre-clinical animal studies, because animals cannot report adverse events.
However, animal toxicity data may be used as a reference for assessing safety in humans.
As per ICH guidelines (ICH E2A–E2F), Pharmacovigilance applies only to human studies.
The History of Pharmacovigilance: From Tragedy to Global Safety
Introduction:
Pharmacovigilance (PV) is the science and activities aimed at detecting, assessing, understanding, and preventing adverse drug reactions (ADRs) or any other drug-related problems. Monitoring drug safety is critical for public health and patient safety globally. PV covers medicines and vaccines throughout their lifecycle—from clinical trials to widespread use.
1. Early Origins: Disasters That Shaped PV (1800s–1960s)
1848 — Chloroform Death
Event:Hannah Greener, a 15-year-old girl, died during toenail surgery under chloroform anesthesia.
Significance: Highlighted that even widely used drugs could have fatal outcomes, prompting early awareness of drug safety.
1937 — Sulfanilamide Elixir Disaster (U.S.)
Event: Over 100 deaths, mostly children, due to a toxic solvent (diethylene glycol) in liquid sulfanilamide.
Outcome: Led to the U.S. Federal Food, Drug, and Cosmetic Act (1938), requiring pre-market safety testing and formal post-marketing surveillance.
1961 — Thalidomide Tragedy (Europe)
Event: ~10,000 infants born with limb deformities and other birth defects due to maternal thalidomide use.
Impact: Catalyst for modern pharmacovigilance; led to stricter global drug safety regulations and formal monitoring systems.
2. Post‑World War II & Mid‑20th Century Developments
After World War II, the pharmaceutical industry expanded rapidly, introducing many new medicines. During this period, it became clear that some serious adverse drug reactions (ADRs) only appeared after drugs were widely used in the general population.
Key Points:
Post-Marketing ADRs: Clinical trials involved small groups and often excluded children, pregnant women, and the elderly. Rare but serious ADRs were often unnoticed until after market release.
Early Reporting Efforts: Hospitals and physicians began documenting unexpected drug reactions, laying the groundwork for formal national reporting systems.
Scientific Awareness: Publications and conferences highlighted the need for structured monitoring rather than relying on anecdotal reports.
Catalyst Event: The thalidomide tragedy (1961) demonstrated the importance of post-marketing surveillance and prompted stricter safety regulations worldwide.
Impact:
Recognition of post-marketing ADRs led to formal pharmacovigilance programs, national reporting systems, and eventually the WHO Programme for International Drug Monitoring (PIDM).
3. Global Movement & Institutionalization
1963–1968 — WHO Turns to Drug Monitoring
16th World Health Assembly adopted resolution for systematic collection of serious ADRs.
1968 — WHO Programme for International Drug Monitoring (PIDM)
Purpose: Share and analyze global drug safety data among member countries.
Founding Members: Australia, Canada, Sweden, UK, USA, Netherlands, New Zealand, Ireland, Germany, Denmark.
Definition: Passive PV is when suspected adverse events are voluntarily reported by healthcare professionals (HCPs) or patients to the Marketing Authorization Holder (MAH), Regulatory Authority, or National PV Coordination Centre (NPVCC).
Passive PV is also called as Spontaneous Reporting, Unsolicited Reporting.
Key Features:
Relies on self-reporting by patients or HCPs.
Captures unexpected or rare adverse events after the drug is on the market.
Forms the foundation of most national PV systems.
Sources of Data:
Voluntary reports from doctors, pharmacists, nurses, or patients.
Submitted to:
National PV centers (e.g., Yellow Card Scheme, UK; PvPI, India)
MAHs / Pharmaceutical companies
Advantages:
Simple and cost-effective.
Good for detecting rare or serious ADRs.
Limitations:
Often under-reported.
Reports may lack details needed for assessing causality.
Example:
In India, patients or HCPs report ADRs to PvPI using forms or mobile apps.
2. Active Pharmacovigilance (Active Surveillance)
Definition: Active PV is a proactive and systematic collection of adverse event data by MAHs from different sources like regulatory authorities, or PV centers.
Active PV is also called as Solicited Reporting.
Key Features:
Planned and structured monitoring.
Collects complete and high-quality data.
Often part of post-marketing surveillance and clinical safety studies.
In addition to surveillance activities, another important step in safety evaluation is expectedness assessment, which determines whether an adverse event is listed in the reference safety information.
Sources of Data:
Clinical Trials (CTs): Pre-marketing safety data.
Post-Marketing Surveillance (PMS): Ongoing monitoring after drug approval.
Medical Records / Hospital Databases: Structured AE data.
Literature Review / Published Case Reports: Journals and scientific publications.
NPVCC / National Databases: Centralized AE reporting systems.
Advantages:
Provides accurate incidence and risk data.
Helps identify trends and safety signals in patients.
Limitations:
Requires resources and planning.
More time-consuming than passive PV.
Examples:
Cohort Event Monitoring (CEM): Patients on a new drug are actively followed to record all adverse events.
According to WHO, passive PV is the cornerstone of routine pharmacovigilance, while active PV ensures high-quality and complete data collection. Both types work together:
Passive PV generates safety signals.
Active PV validates and quantifies risks
Key Takeaway:
Understanding passive and active PV is essential for healthcare professionals, students, and regulatory authorities. While passive PV is cost-effective and widely used, active PV provides reliable and detailed safety data to protect public health.
“Pharmacovigilance keeps medicines safe and patients protected. By understanding its history, types, and importance, we can contribute to safer healthcare for all. Stay curious, report responsibly, and be part of the journey in drug safety!”
“Your insights and experiences can help all of us grow in PV—let’s learn and improve drug safety together!”
If you are new to drug safety, understanding standard terminology is essential. Explore our Key Pharmacovigilance Terminologies guide for clear beginner-friendly definitions.
Frequently Asked Questions (FAQs)
Q1: What is pharmacovigilance?
Answer: Pharmacovigilance (PV) is the science of monitoring the safety of medicines and detecting, assessing, and preventing adverse drug reactions (ADRs) to protect patients.
Q2: Why is pharmacovigilance important?
Answer: Pharmacovigilance is important because it ensures medicines are safe for patients. It helps identify side effects, reduce risks, and improve patient safety.
Q3: What is an adverse drug reaction (ADR)?
Answer: An adverse drug reaction (ADR) is an unwanted or harmful effect experienced after taking a medicine at normal doses.
Q4: What are the main objectives of pharmacovigilance?
Answer: The main objectives are:
Detect adverse drug reactions
Ensure patient safety
Monitor drug risk–benefit balance
Promote safe use of medicines
Q5: Who reports adverse drug reactions?
Answer: ADRs can be reported by:
Doctors
Pharmacists
Nurses
Patients
Pharmaceutical companies
Q6: What is the history of pharmacovigilance?
Answer: Pharmacovigilance developed after serious drug safety incidents showed the need for monitoring medicine safety. Over time, global systems were created to track side effects and protect patients.
Q7: What are the types of pharmacovigilance?
Answer: Common types include:
Passive surveillance (spontaneous reporting)
Active surveillance (planned monitoring)
Cohort event monitoring
Q8: Can freshers build a career in pharmacovigilance?
Answer: Yes. Many freshers from pharmacy and life-science backgrounds start careers in pharmacovigilance with roles like Drug Safety Associate or PV Associate
Practicing Narrative Writing in Pharmacovigilance (PV): Learner Notes with Simulated ICSR Examples Introduction While learning pharmacovigilance, I realized that understanding the guidelines and standard structure of narrative writing alone is not enough to feel confident in real-world PV case processing. Narrative writing started to make more sense to me only when I began practicing it repeatedly using realistic scenarios. As part of my learning process, I practiced narrative writing using simulated (dummy) Individual Case Safety Report (ICSR) examples . These cases do not involve real patients or real safety data, but they closely resemble the types of cases handled during routine pharmacovigilance work. I compiled all my practice cases in this post so that I can revisit, revise, and deepen my understanding of narrative writing over time. It would also be helpful for other PV learners who want to understand narrative writing through practical examples collected in one place. đź”— **Re...
Learning ICSR Processing in Pharmacovigilance: Practical Case Scenarios for Beginners Last Updated: January 20 26 Disclaimer ✻This content has been created strictly for educational and self-learning purposes . ✻ As a Pharmacovigilance fresher , I practiced these simulated (dummy) ICSR case scenarios to strengthen my understanding of ICSR processing concepts. ✻ All drugs, case scenarios, timelines, and outcomes mentioned are completely fictional and do not represent real patients, real safety reports, or any confidential company data. ✻ This content is not intended to replace official regulatory guidance. Introduction Individual Case Safety Reports (ICSRs) are a core component of Pharmacovigilance and drug safety activities . While regulatory guidelines explain the theory, developing practical understanding requires hands-on case-based learning . To understand the complete workflow of ICSR processing, read our guide on ICSR Processing in Pharmacovigilance: Step-by-Step Workflow. As ...
Key Terminologies in Pharmacovigilance Explained (ADR, AE, SAE, SUSAR, ICSR Guide) Pharmacovigilance involves monitoring the safety of medicines and identifying adverse effects associated with drug use. To understand drug safety reporting, it is important to learn the key pharmacovigilance terminologies used in clinical trials and post-marketing surveillance. In this guide, we explain important pharmacovigilance terms such as Adverse Event (AE), Adverse Drug Reaction (ADR), Serious Adverse Event (SAE), SUSAR, ICSR, signal detection, and risk management with practical examples for beginners.
Adverse Drug Reactions( ADR): Types, Minimum Criteria for ICSR, and Challenge-Dechallenge-Rechallenge Explained Introduction Adverse Drug Reactions (ADRs) are a central concept in pharmacovigilance because they directly affect patient safety and regulatory decision-making throughout the lifecycle of a medicinal product. Identifying, evaluating, and reporting ADRs helps healthcare professionals and regulatory authorities detect potential drug safety issues. This article explains the different types of ADRs, the four minimum criteria required for a valid Individual Case Safety Report (ICSR), and the concepts of challenge, dechallenge, and rechallenge used in causality assessment. What is an Adverse Drug Reaction (ADR)? An Adverse Drug Reaction (ADR) is a harmful and unintended response to a medicinal product for which a causal relationship between the drug and the event is suspected. To understand the basic pharmacovigilance terminology used in drug safety, read our guide on Key Terminol...
.png)
Comments
Post a Comment